1
|
Moncada-Basualto M, Saavedra-Olavarría J, Rivero-Jerez PS, Rojas C, Maya JD, Liempi A, Zúñiga-Bustos M, Olea-Azar C, Lapier M, Pérez EG, Pozo-Martínez J. Assessment of the Activity of Nitroisoxazole Derivatives against Trypanosoma cruzi. Molecules 2024; 29:2762. [PMID: 38930828 PMCID: PMC11207111 DOI: 10.3390/molecules29122762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2024] [Revised: 05/31/2024] [Accepted: 06/04/2024] [Indexed: 06/28/2024] Open
Abstract
The development of new compounds to treat Chagas disease is imperative due to the adverse effects of current drugs and their low efficacy in the chronic phase. This study aims to investigate nitroisoxazole derivatives that produce oxidative stress while modifying the compounds' lipophilicity, affecting their ability to fight trypanosomes. The results indicate that these compounds are more effective against the epimastigote form of T. cruzi, with a 52 ± 4% trypanocidal effect for compound 9. However, they are less effective against the trypomastigote form, with a 15 ± 3% trypanocidal effect. Additionally, compound 11 interacts with a higher number of amino acid residues within the active site of the enzyme cruzipain. Furthermore, it was also found that the presence of a nitro group allows for the generation of free radicals; likewise, the large size of the compound enables increased interaction with aminoacidic residues in the active site of cruzipain, contributing to trypanocidal activity. This activity depends on the size and lipophilicity of the compounds. The study recommends exploring new compounds based on the nitroisoxazole skeleton, with larger substituents and lipophilicity to enhance their trypanocidal activity.
Collapse
Affiliation(s)
- Mauricio Moncada-Basualto
- Instituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, San Joaquín 8940577, Chile; (M.M.-B.); (C.R.); (M.Z.-B.)
| | - Jorge Saavedra-Olavarría
- Department of Organic Chemistry, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, San Joaquin 7820436, Chile; (J.S.-O.); (P.S.R.-J.)
| | - Paula S. Rivero-Jerez
- Department of Organic Chemistry, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, San Joaquin 7820436, Chile; (J.S.-O.); (P.S.R.-J.)
| | - Cristian Rojas
- Instituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, San Joaquín 8940577, Chile; (M.M.-B.); (C.R.); (M.Z.-B.)
- Laboratory of Free Radicals and Antioxidants, Faculty of Chemical and Pharmaceutical Science, Universidad de Chile, Olivos 1007, Independencia 8380544, Chile;
| | - Juan D. Maya
- Programa de Farmacología Molecular y Clínica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Av. Independencia 1027, Independencia 8380453, Chile;
| | - Ana Liempi
- Programa de Biología Integrativa, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Av. Independencia 1027, Independencia 8380453, Chile;
| | - Matías Zúñiga-Bustos
- Instituto Universitario de Investigación y Desarrollo Tecnológico, Universidad Tecnológica Metropolitana, San Joaquín 8940577, Chile; (M.M.-B.); (C.R.); (M.Z.-B.)
| | - Claudio Olea-Azar
- Laboratory of Free Radicals and Antioxidants, Faculty of Chemical and Pharmaceutical Science, Universidad de Chile, Olivos 1007, Independencia 8380544, Chile;
| | - Michel Lapier
- Centro de Investigación, Desarrollo e Innovación de Productos Bioactivos (CinBio), Escuela de Química y Farmacia, Facultad de Farmacia, Universidad de Valparaíso, Av. Gran Bretaña 1093, Valparaiso 2360102, Chile;
| | - Edwin G. Pérez
- Department of Organic Chemistry, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, San Joaquin 7820436, Chile; (J.S.-O.); (P.S.R.-J.)
| | - Josué Pozo-Martínez
- Programa de Farmacología Molecular y Clínica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Av. Independencia 1027, Independencia 8380453, Chile;
- Laboratorio de Química—Médica, Facultad de Ciencia y Tecnología, Universidad del Azuay, Av. 24 de Mayo 777, Cuenca 010204, Ecuador
| |
Collapse
|
2
|
Castanha APM, Almeida-Terassi LM, Guardado-Yordi E, Matos MJ, Maistro EL. Cytogenotoxicity assessment of 3-(3,4-dihydroxyphenyl)-7,8-dihydroxycoumarin on HepG2/C3A cells and leukocytes. J Appl Toxicol 2023; 43:323-334. [PMID: 36000810 DOI: 10.1002/jat.4384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/17/2022] [Accepted: 08/21/2022] [Indexed: 01/17/2023]
Abstract
3-(3,4-Dihydroxyphenyl)-7,8-dihydroxycoumarin is a newly synthesized coumarin derivative with a potent antioxidant effect. The aim of the present study is to investigate the safety of this compound, determining the in vitro cytotoxic and genotoxic in human peripheral blood mononuclear cells (PBMC) and in HepG2/C3A cells. Cell viability has been investigated by the trypan blue staining test and MTT assay and the genotoxicity by the comet assay and micronucleus test, using concentrations between 0.01 and 10 μg/ml. The compound proved to be noncytotoxic in both cell lines, at all tested concentrations, protecting the cells from the DNA damage. In addition, this molecule does not show clastogenic/aneugenic effects when performing the micronucleus test with cytokinesis blockade. Based on the obtained data, and the conditions of the experiments, we can conclude that the 3-(3,4-dihydroxyphenyl)-7,8-dihydroxycoumarin is a safe molecule up to a concentration of 10 μg/ml, which encourages further studies aiming to explore its potential as a drug candidate.
Collapse
Affiliation(s)
| | | | | | - Maria João Matos
- Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.,CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal
| | - Edson Luis Maistro
- Marilia Medical School, FAMEMA, Marilia, Brazil.,Faculty of Philosophy and Sciences, Speech and Hearing Therapy Department, São Paulo State University-UNESP, Marília, Brazil
| |
Collapse
|
3
|
Quintero-Pertuz H, Veas-Albornoz R, Carrillo I, González-Herrera F, Lapier M, Carbonó-Delahoz E, Del Olmo E, Feliciano AS, Kemmerling U, Olea-Azar C, Delporte C, Maya JD. Trypanocidal effect of alcoholic extract of Castanedia santamartensis (Asteraceae) leaves is based on altered mitochondrial function. Biomed Pharmacother 2022; 148:112761. [PMID: 35240521 DOI: 10.1016/j.biopha.2022.112761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Revised: 02/23/2022] [Accepted: 02/24/2022] [Indexed: 11/26/2022] Open
Abstract
The deficit of effective treatments for Chagas disease has led to searching for new substances with therapeutic potential. Natural products possess a wide variety of chemical structural motifs and are thus a valuable source of diverse lead compounds for the development of new drugs. Castanedia santamartensis is endemic to Colombia, and local indigenous communities often use it to treat skin sores from leishmaniasis; however, its mechanism of action against the infective form of Trypanosoma cruzi has not been determined. Thus, we performed chemical and biological studies of two alcoholic leaf extracts of C. santamartensis to identify their active fractions and relate them to a trypanocidal effect and evaluate their mechanism of action. Alcoholic extracts were obtained through cold maceration at room temperature and fractionated using classical column chromatography. Both ethanolic and methanolic extracts displayed activity against T. cruzi. Chemical studies revealed that kaurenoic acid was the major component of one fraction of the methanolic extract and two fractions of the ethanolic extract of C. santamartensis leaves. Moreover, caryophyllene oxide, kaurenol, taraxasterol acetate, pentadecanone, and methyl and ethyl esters of palmitate, as well as a group of phenolic compounds, including ferulic acid, caffeic acid, chlorogenic acid, myricetin, quercitrin, and cryptochlorogenic acid were identified in the most active fractions. Kaurenoic acid and the most active fractions CS400 and CS402 collapsed the mitochondrial membrane potential in trypomastigotes, demonstrating for the first time the likely mechanism against T. cruzi, probably due to interactions with other components of the fractions.
Collapse
Affiliation(s)
- Helena Quintero-Pertuz
- Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Dr. Carlos Lorca Tobar 964, Independencia, Chile
| | - Ruben Veas-Albornoz
- Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Dr. Carlos Lorca Tobar 964, Independencia, Chile
| | - Ileana Carrillo
- Programa de Farmacología Molecular y Clínica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avenida Independencia 1027, Independencia, Santiago, Chile
| | - Fabiola González-Herrera
- Programa de Farmacología Molecular y Clínica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avenida Independencia 1027, Independencia, Santiago, Chile
| | - Michel Lapier
- Departamento de Química Inorgánica y Analítica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Dr. Carlos Lorca Tobar 964, Independencia, Chile
| | - Eduino Carbonó-Delahoz
- Herbario UTMC, Carrera 32 No. 22-08 Santa Marta D.T.C.H, Universidad del Magdalena, Colombia
| | - Esther Del Olmo
- Departamento de Ciencias Farmacéuticas, Área de Química Farmacéutica, Facultad de Farmacia, Centro de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain
| | - Arturo San Feliciano
- Departamento de Ciencias Farmacéuticas, Área de Química Farmacéutica, Facultad de Farmacia, Centro de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; Programa de Pós-graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí, UNIVALI, Itajaí, SC, Brazil
| | - Ulrike Kemmerling
- Programa de Anatomía y Biología del Desarrollo, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avenida Independencia 1027, Independencia, Santiago, Chile
| | - Claudio Olea-Azar
- Departamento de Química Inorgánica y Analítica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Dr. Carlos Lorca Tobar 964, Independencia, Chile
| | - Carla Delporte
- Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Dr. Carlos Lorca Tobar 964, Independencia, Chile.
| | - Juan D Maya
- Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Dr. Carlos Lorca Tobar 964, Independencia, Chile; Programa de Farmacología Molecular y Clínica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avenida Independencia 1027, Independencia, Santiago, Chile.
| |
Collapse
|